Microbial manipulation as primary therapy for Crohn's disease

作     者：Randy S Longman Arun Swaminath 

作者机构：Division of Digestive and Liver DiseaseDepartment of MedicineColumbia University Medical CenterNew YorkNY 10032United States 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2013年第19卷第10期

页      面：1513-1516页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Inflammatory bowel disease Rifaximin Microbiome 

摘      要：While antimicrobials are clinically effective in preventing post-operative recurrence,the role for antibiotics in primary therapy for Crohn s disease(CD) remains *** recent multicenter phase 2 trial by Prantera et al received wide attention because it demonstrated an increase in the week 12 remission rate in patients with moderately active CD treated with rifaximin and renewed interest in microbial manipulation as primary therapy for *** this commentary,we discuss aspects of durability,immune cell polarization,and safety of microbial manipulation as primary therapy for CD.